Please login to the form below

Not currently logged in
Email:
Password:

Suboxone

This page shows the latest Suboxone news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories.

Latest news

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    That would help counteract a major setback for the business in the US a few weeks back when it lost a patent infringement lawsuit involving its main product Suboxone (buprenorphine and ... RBP-6000 is a long-acting form of buprenorphine that can be

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    The UK-listed company - which was spun out of Reckitt Benckiser three years ago - generates the bulk of its revenues from Suboxone (buprenorphine and naloxone), an oral film product used for ... As it stands, those two companies remain blocked from

  • Reckitt to spin-off pharma unit as Indivior Reckitt to spin-off pharma unit as Indivior

    Demerged business will focus on opioid dependence product Suboxone.  . UK firm Reckitt Benckiser has confirmed detailed of its plans to demerge its pharmaceuticals business. . ... RBP generates nearly all its revenues from Suboxone (buprenorphine and

  • Reckitt Benckiser confirms pharma spin-off plans Reckitt Benckiser confirms pharma spin-off plans

    The pharma unit generates nearly all its revenues from Suboxone (buprenorphine and naloxone), used for the treatment of opioid dependence, and - while prescription volumes for the product grew in the US - ... RB Pharma is trying to expand its product

  • Reckitt Benckiser may spin out pharma division Reckitt Benckiser may spin out pharma division

    Reckitt's main pharmaceutical product is Suboxone (buprenorphine and naloxone) for the treatment of opioid dependence, which has been under pressure thanks to an increasingly competitive market space, and revenues for ... One reason for the decline is

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Indivior will not be without its challenges as sales of its off-patent opioid addiction treatment Suboxone continue to slump.

  • Pharma deals during July 2014 Pharma deals during July 2014

    However, with revenues falling by 8 per cent in H1 2014 as a result of US generic competition for Suboxone (the pharma unit's top selling drug), it remains to be

  • Pharma deals during May 2014 Pharma deals during May 2014

    considered. A capital markets solution is emerging as a strong option.” The difficulty is that Suboxone (for treatment of drug addiction) sales are being hit by generic competition.

  • Pharma deals during February 2013 Pharma deals during February 2013

    November 2012 may distract attention from the noise surrounding the Suboxone film versus tablets debate.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics